Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 5/20 | 0.43 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | SCN1A | P35498 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14731243 | 0.83 | XDH (0.56) | MAPTGAASCN9AKCNH2SCN10A | |
| SCHEMBL2360415 | 0.82 | MAPT (0.51) | NOTUMMAPTSCN10AADORA3POLB | |
| SCHEMBL14910868 | 0.78 | KIF11 (0.47) | NOTUMMAPTMAPK1L3MBTL1KDM4E | |
| SCHEMBL167088 | 0.78 | MAPT (0.67) | MAPTMAPK1L3MBTL1KDM4EGAA | |
| SCHEMBL27028221 | 0.78 | SCN9A (0.60) | MAPTL3MBTL1GAANPC1RAB9A | |
| SCHEMBL1853118 | 0.77 | MAPT (0.41) | MAPTMAPK1L3MBTL1GAANPC1 | |
| SCHEMBL10357934 | 0.77 | RAB9A (0.65) | MAPTMAPK1KDM4ENPC1RAB9A | |
| SCHEMBL27860134 | 0.77 | L3MBTL1 (0.40) | NOTUMMAPTMAPK1L3MBTL1KDM4E | |
| SCHEMBL244618 | 0.75 | ALPL (0.54) | MAPTMAPK1KDM4ENPC1RAB9A | |
| SCHEMBL7254718 | 0.75 | NOTUM (0.40) | NOTUMMAPTMAPK1L3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10960007-B2 | Pharmacologically active aryl-substituted pyrazolo[1,5-a]pyrimidine derivatives | RICHTER GEDEON NYRT. (HU) | 2021-03-30 | — | — | US | disclosed |
| US-20200061068-A1 | Pharmacologically Active Aryl-Substituted Pyrazolo[1,5-a]Pyrimidine Derivatives | RICHTER GEDEON NYRT. (HU) | 2020-02-27 | — | — | US | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| EP-2118067-B1 | NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS | SIENA BIOTECH SPA (IT) | 2013-05-08 | — | — | EP | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
| US-6649759-B2 | Pyrazolo(1,5-a)pyrimidine derivatives; treating feeding, cardiovascular and psychological disorders | PFIZER INC. | 2003-11-18 | — | — | US | disclosed |
| US-20030100546-A1 | Neuropeptide Y antagonists | ELLIOTT RICHARD L (US) | 2003-05-29 | — | — | US | disclosed |
| US-20020061897-A1 | Neuropeptide Y antagonists | ELLIOTT RICHARD L (US) | 2002-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100546-A1 | Neuropeptide Y antagonists | NPY1R, NPY2R, GIPR | NOTUM 2414/4885MAPT 4324/4885MAPK1 704/4885 |
| US-20200061068-A1 | Pharmacologically Active Aryl-Substituted Pyrazolo[1,5-a]Pyrimidine Derivatives | GABRA5, P2RX5, P2RY1 | NOTUM 3888/4885MAPT 2067/4885MAPK1 1457/4885 |
| US-10960007-B2 | Pharmacologically active aryl-substituted pyrazolo[1,5-a]pyrimidine derivatives | GABRA5, P2RX5, P2RY1 | NOTUM 3888/4885MAPT 2067/4885MAPK1 1457/4885 |
| US-20020061897-A1 | Neuropeptide Y antagonists | NPY1R, NPY2R, GIPR | NOTUM 2414/4885MAPT 4324/4885MAPK1 704/4885 |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PPP3CB, PTPRG | NOTUM 2585/4885MAPT 417/4885MAPK1 1350/4885 |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | NOTUM 2328/4885MAPT 519/4885MAPK1 1698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.